Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Cash & Equivalents (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Cash & Equivalents data on record, last reported at $797.8 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 1119.09% year-over-year to $797.8 million; the TTM value through Dec 2025 reached $797.8 million, up 1119.09%, while the annual FY2025 figure was $797.8 million, 1119.09% up from the prior year.
  • Cash & Equivalents reached $797.8 million in Q4 2025 per CAI's latest filing, up from $754.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $797.8 million in Q4 2025 and bottomed at $65.4 million in Q4 2024.